Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Private Label Competition For Zegerid OTC Sets Sail With Perrigo Launch

Executive Summary

Perrigo's omeprazole and sodium bicarbonate capsules indicated for the treatment of frequent heartburn will bear labeling that has been through several updates since the first PPI became available OTC in 2004.


Related Content

Perrigo's Next Private Label First Lands With Second Thoughts On Outlook
Perrigo Draws On OTC Strength For Private Label Nexium 24HR Launch
Benefit From OTC Switches Supported In Study Of PPIs' Outpatient Impact
Culture Shock In Europe For Perrigo With Branded Consumer Business
Zegerid OTC, Private Label Omeprazole Add Drug Interaction Warnings
In Brief
Perrigo moves forward with generic Zegerid OTC
Zegerid patents ruled invalid


Related Companies

Related Deals

What to read next




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts